Surgery is thought to be life-saving for people who have ischemic mitral regurgitation, but it is unknown whether surgical repair or surgical replacement of the mitral valve is the better procedure.

Bioprosthetic valves lasts about 10-15 years. These are usually obtained from animals or human organ donors. Tissue valves seem to improve the patient’s hemodynamics, but tend to stiffen in 10-15 ...

Patient will be placed under general anesthesia. An endotracheal tube will be inserted into the patient’s windpipe and connected to a ventilator to assist the patient’s breathing. Another probe will ...

Edwards Lifesciences has claimed an FDA approval for its Sapien M3 transcatheter mitral valve replacement system—marking the ...

Almost 20 years’ worth of follow-up in an international registry shows that patients with degenerative mitral regurgitation who underwent mitral valve (MV) repair had better survival, fewer ...

CONGENITAL mitral stenosis, sufficiently severe to cause recurrent heart failure and syncopal episodes in infancy, is rarely compatible with life beyond two years of age. 1 Except for 1 reported case ...

IRVINE, Calif., March 31, 2022 /PRNewswire/ -- Edwards Lifesciences (NYSE: EW) today announced it received approval from the U.S. Food and Drug Administration (FDA) for the MITRIS RESILIA valve, a ...

Patients who underwent mitral valve replacement had a more than threefold higher 10-year rate of infective endocarditis than those at moderate risk for the disease, whereas undergoing mitral valve ...

For high-risk surgical patients with severe symptomatic mitral regurgitation (MR), insertion of the Tendyne transcatheter mitral valve replacement (TMVR; Abbott) using a cardiac transapical approach ...

The Sapien M3 device is the first approved mitral regurgitation treatment to use a transseptal approach, Edwards said.

Edwards Lifesciences (NYSE: EW) today announced the company’s SAPIEN M3 mitral valve replacement system is the first ...